William J Link Phd sold $980k of TARS
director at Tarsus Pharmaceuticals, Inc.. 12,500 shares at an average of $78.38, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$980k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001228684-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | MOption exercise Common Stock10b5-1 | +201 | - | - | 106,987 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -11,675 | $78.33 | $915k | 95,312 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -759 | $79.00 | $60k | 94,553 | 25 d ago |
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -66 | $80.01 | $5,281 | 94,487 | 25 d ago |
| Sep 15, 2026 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -201 | $0.00 | $0 | 605 | 25 d ago |
Related signals
Other insiders at Tarsus Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $906k 10,000 shares | -1% | |
| 55Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $1.2M 13,953 shares | -105% | |
| 31Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $388k 4,564 shares | -5% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $801k 10,000 shares | -1% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $898k 11,578 shares | -50% | |
| 78Notable | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $2.4M 34,603 shares | -51% | |
| 45Moderate | Tarsus Pharmaceuticals, Inc. | Jeffrey S Farrow See Remarks | $440k 6,430 shares | -13% | |
| 38Weak | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $495k 6,000 shares | -1% | |
| 34Weak | Tarsus Pharmaceuticals, Inc. | Dianne C. Whitfield Chief Human Resources Officer | $592k 7,397 shares | -16% | |
| 40Moderate | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $1.9M 22,946 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.